Brief: Medipost receives patent
06/12/2017 02:14
Dec 6 (Reuters) - Medipost Co Ltd 078160.KQ :
* Says it receives patent named TSP-1, TSP-2, IL-17BR and
HB-EGF
associated with stem cell activities and applications thereof
* Says patent number is 13 189 750.6
Source text in Korean: https://goo.gl/2f9ZB2
Further company coverage: 078160.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; Reuters Messaging:
Yinglan.Ma@thomsonreuters.com@reuters.net))
Recent news on Medipost Co
See all newsBrief: Medipost's Cartistem® Meets All Primary And Secondary Endpoints In Japan Phase 3 Trial And Demonstrates Statistically Significant Efficacy Gains Versus Active Control
Brief: Medipost Inc. Submits Ind Amendment With U.S. Food And Drug Administration To Initiate Phase Iii Trial
Brief: Medipost Co Q3 Operating Profit 2 Billion Won, Swings To Profit From Year Earlier
Brief: Medipost To Conduct Capital Increase Of 120 Billion Won
Brief: Medipost Co To Acquire 46 Billion Won Worth Of Shares In Unit Medipost America